fulvestrant has been researched along with hki 272 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Avogadri-Connors, F; Cutler, RE; Dowsett, M; Guest, SK; Johnston, SR; Lalani, AS; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Rani, A; Ribas, R; Schuster, E; Simigdala, N; Thornhill, A | 1 |
| Arnedos, M; Arteaga, CL; Baselga, J; Bidard, FC; Boni, V; Brufksy, AM; Bryce, R; Cai, Y; Cervantes, A; Chandarlapaty, S; de la Fuente, MI; Dujka, M; Eli, LD; Gavrila, EI; Gonzàlez-Farré, X; Gorelick, AN; Hyman, DM; Jhaveri, K; Juric, D; Lalani, AS; Lanman, RB; Loi, S; Lu, J; Mann, G; Mau-Sørensen, M; Mayer, IA; Melcer, M; Meric-Bernstam, F; Moreno, V; Nagy, RJ; Piha-Paul, SA; Samoila, A; Saura, C; Scaltriti, M; Schram, AM; Schwartzberg, LS; Selcuklu, SD; Shapiro, GI; Smyth, LM; Sohn, J; Solit, DB; Spanggaard, I; Taylor, BS; Ulaner, GA; Won, HH; Xu, F; Zimel, C | 1 |
| Abraham, J; Baird, RD; Bliss, JM; Braybrooke, JP; Bye, H; Cameron, D; Cutts, R; Gevensleben, H; Hubank, M; Kernaghan, S; Kilburn, LS; Kingston, B; Macpherson, IR; Martin, S; Moretti, L; Oikonomidou, O; Randle, K; Rea, D; Ring, A; Roylance, R; Shaaban, A; Snowdon, C; Stephens, P; Turner, NC; Tuthill, M; Wardley, AM; Wilkinson, K; Winter, MC | 1 |
| Isaacs, C; O'Regan, R; O'Shaughnessy, JA | 1 |
| Anderson, J; Bose, R; Bryce, R; Bucheit, L; Carey, LA; Cobleigh, M; Ellis, MJ; Freedman, RA; Gao, F; Goetz, MP; Haas, B; Jones, JM; Kimmick, G; Lalani, AS; Lin, NU; Lu, J; Luo, J; Ma, CX; Marcom, PK; Nangia, JR; Pegram, MD; Pluard, TJ; Thomas, S; Valdez-Albini, F; Winer, EP | 1 |
| Arnedos, M; Arteaga, CL; Bell, JSK; Bhave, M; Bidard, FC; Bose, R; Brufsky, A; Burkard, ME; Chia, S; Crown, J; de Miguel, MJ; DiPrimeo, D; Eli, LD; Frazier, A; Gal-Yam, EN; Gambardella, V; Garcia-Saenz, JÁ; Goldman, JW; Guerrero-Zotano, A; Hanker, AB; Hurvitz, SA; Jhaveri, K; Loi, S; Ma, C; Park, H; Peterson, L; Piha-Paul, SA; Prat, A; Rapael, A; Reid, S; Saura, C; Solit, DB; Spanggaard, I; Stemmer, SM; Suga, JM; Unni, N; Vinayak, S; Waisman, J; Wildiers, H; Wong, A; Yang, ES; Ye, D | 1 |
4 trial(s) available for fulvestrant and hki 272
| Article | Year |
|---|---|
Efficacy and Determinants of Response to HER Kinase Inhibition in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Treatment Outcome | 2020 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Female; Fulvestrant; Genotype; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Prospective Studies; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2020 |
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Quinolines; Receptor, ErbB-2 | 2022 |
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
3 other study(ies) available for fulvestrant and hki 272
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogens; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms, Hormone-Dependent; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2018 |
Neratinib: an option for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |